DelMar Pharmaceuticals Inc (Nasdaq: DMPI), a biopharmaceutical company focused on the development and commercialisation of new cancer therapies, announced yesterday that it has named three oncologists to its Scientific Advisory Board.
The company has added Dr David Reardon, clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and a professor of medicine at the Harvard Medical School to its Scientific Advisory Board; Dr Timothy Cloughesy, professor of neurology at the David Geffen School of Medicine at the University of California, Los Angeles and a member of the UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center; Dr Nicholas Butowski, a neuro-oncologist practicing at UCSF Medical Center in San Francisco, California, and director of translational research in neuro-oncology and a researcher at the Brain Tumor Center.
These new advisors join the present Scientific Advisory Board members Dr John de Groot, chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Centre and Dr Napoleone Ferrara, scientist and distinguished professor of pathology and a distinguished adjunct professor of ophthalmology and pharmacology at the University of California, San Diego. Dr Ferrara will serve as chairman of the company's Scientific Advisory Board.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients